Listen

Hepatitis C

Gilead Sciences, the drugmaker behind the experimental COVID-19 treatment remdesivir, spent more on lobbying Congress and the administration in the first quarter of 2020 than it ever has before, according to federal filings.

The pharmaceutical company spent $2.45 million on lobbying in the first three months of the year, a 32% increase over the $1.86 million it spent in the first quarter of 2019.

Editor's note: On June 29, this story was updated to include comment from the Centers for Disease Control and Prevention about the transmissibility of hepatitis C virus in semen.

An Ohio man who has the hepatitis C virus was sentenced to 18 months in prison on June 14 for spitting at Cleveland police and medics, according to a news report.

The rise of heroin usage and related hepatitis C infections in central Ohio has local health officials discussing plans to combat the issue, including a needle exchange program.